Correlation Between Blueprint Medicines and Kymera Therapeutics
Can any of the company-specific risk be diversified away by investing in both Blueprint Medicines and Kymera Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Blueprint Medicines and Kymera Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Blueprint Medicines Corp and Kymera Therapeutics, you can compare the effects of market volatilities on Blueprint Medicines and Kymera Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Blueprint Medicines with a short position of Kymera Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Blueprint Medicines and Kymera Therapeutics.
Diversification Opportunities for Blueprint Medicines and Kymera Therapeutics
0.2 | Correlation Coefficient |
Modest diversification
The 3 months correlation between Blueprint and Kymera is 0.2. Overlapping area represents the amount of risk that can be diversified away by holding Blueprint Medicines Corp and Kymera Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Kymera Therapeutics and Blueprint Medicines is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Blueprint Medicines Corp are associated (or correlated) with Kymera Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Kymera Therapeutics has no effect on the direction of Blueprint Medicines i.e., Blueprint Medicines and Kymera Therapeutics go up and down completely randomly.
Pair Corralation between Blueprint Medicines and Kymera Therapeutics
Given the investment horizon of 90 days Blueprint Medicines Corp is expected to generate 1.04 times more return on investment than Kymera Therapeutics. However, Blueprint Medicines is 1.04 times more volatile than Kymera Therapeutics. It trades about 0.22 of its potential returns per unit of risk. Kymera Therapeutics is currently generating about -0.14 per unit of risk. If you would invest 8,440 in Blueprint Medicines Corp on August 24, 2024 and sell it today you would earn a total of 1,317 from holding Blueprint Medicines Corp or generate 15.6% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 95.65% |
| Values | Daily Returns |
Blueprint Medicines Corp vs. Kymera Therapeutics
Performance |
| Timeline |
| Blueprint Medicines Corp |
| Kymera Therapeutics |
Blueprint Medicines and Kymera Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Blueprint Medicines and Kymera Therapeutics
The main advantage of trading using opposite Blueprint Medicines and Kymera Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Blueprint Medicines position performs unexpectedly, Kymera Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kymera Therapeutics will offset losses from the drop in Kymera Therapeutics' long position.| Blueprint Medicines vs. Lyra Therapeutics | Blueprint Medicines vs. Hookipa Pharma | Blueprint Medicines vs. Cingulate Warrants | Blueprint Medicines vs. SAB Biotherapeutics |
| Kymera Therapeutics vs. Foghorn Therapeutics | Kymera Therapeutics vs. Shattuck Labs | Kymera Therapeutics vs. Monte Rosa Therapeutics | Kymera Therapeutics vs. Nurix Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Complementary Tools
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |